Neuroprotection by canagliflozin in a Huntington’s disease model: role of HIF-1α and PI3K/AKT signaling
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04891-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Ali M Elgindy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, 11829, Egypt. ali-elgindy@eru.edu.eg. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Huntington Disease, Proto-Oncogene Proteins c-akt, Neuroprotective Agents. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Egyptian Russian University.
Abstract (Originalsprache)
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and metabolic dysfunction, largely driven by mitochondrial impairment and defective energy metabolism. Altered signaling through hypoxia-inducible factor-1α (HIF-1α) and PI3K/AKT cascades contributes to neuronal vulnerability. Canagliflozin (Cana), a sodium–glucose cotransporter-2 inhibitor, has shown cognitive benefits in experimental studies. Here, we evaluated whether Cana mitigates 3-nitropropionic acid (3NP, 10 mg/kg, i.p., 14 days)-induced HD-like neurotoxicity in rats. Animals received Cana (5 or 10 mg/kg, p.o.) daily for 14 days, followed by behavioral assessments (open-field, Morris water maze, novel object recognition), histopathology, immunohistochemistry, and biochemical assays. Cana treatment significantly improved locomotor and memory performance, reduced striatal histopathological alterations, and attenuated GFAP immunoreactivity. Mechanistically, Cana upregulated HIF-1α and downstream GLUT1/GLUT3/HKII, restored PI3K/AKT/CREB/BDNF signaling, and enhanced SIRT1/PGC-1α/Nrf2 antioxidant responses, while suppressing inflammatory mediators and caspase-3 activation. These findings highlight Cana as a promising disease-modifying strategy for HD by targeting both energy metabolism and pro-survival pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, 11829, Egypt. ali-elgindy@eru.edu.eg.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, 11829, Egypt.
- College of Pharmacy, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq.
Förderung
- Egyptian Russian University
Zitieren
APA
Elgindy, A. M., El-Awady, E. E., El-Sayed, N. M., El-Orabi, N. F., & Atwa, A. M. (2025). Neuroprotection by canagliflozin in a Huntington’s disease model: role of HIF-1α and PI3K/AKT signaling. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04891-5
Vancouver
Elgindy AM, El-Awady EE, El-Sayed NM, El-Orabi NF, Atwa AM. Neuroprotection by canagliflozin in a Huntington’s disease model: role of HIF-1α and PI3K/AKT signaling. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04891-5
BibTeX
@article{Elgindy2025,
author = {Elgindy, Ali M and El-Awady, El-Sayed E and El-Sayed, Norhan M and El-Orabi, Naglaa F and Atwa, Ahmed M},
title = {Neuroprotection by canagliflozin in a Huntington’s disease model: role of HIF-1α and PI3K/AKT signaling},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04891-5}
}
EUVIMED